Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 6.5% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a biotechnology company known for its innovative medicines to treat serious diseases. The stock had a bearish movement today amidst recent market volatility.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 6.5% on May 8, 2025 13:45

• The stock price of Regeneron Pharmaceuticals experienced a significant decline today, despite a slight increase in the current market session.
• The downward trend in the stock price could be attributed to the overall market sentiment affecting biotech and pharmaceutical companies.
• Investors might be reacting to the stock's performance over the past month and year, where it has shown a notable decrease, possibly leading to profit-taking or market corrections.
• While Regeneron Pharmaceuticals has historically outperformed the market over the long term, short-term fluctuations can be influenced by various factors, including industry news and market conditions.

REGN Price Chart

REGN Technical Analysis

REGN News

Price Over Earnings Overview: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals ( NASDAQ:REGN )

In the current market session, Regeneron Pharmaceuticals Inc. REGN price is at $563.91, after a 0.97% increase. However, over the past month, the stock fell by 2.22%, and in the past year, by 41.74%.

https://www.benzinga.com/insights/news/25/05/45254301/price-over-earnings-overview-regeneron-pharmaceuticals

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )

Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 12.37% on an annualized basis producing an average annual return of 23.51%. Currently, Regeneron Pharmaceuticals has a market capitalization of $65.41 billion.

https://www.benzinga.com/insights/news/25/05/45199490/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-this-much-today

Trending Today

Pepe ($PEPE) Crypto Forecast: Up 46.0% Today

Injective ($INJ) Crypto Forecast: Up 17.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 15.4% Today

XRP ($XRP) Crypto Forecast: Up 8.4% Today

Ethereum ($ETH) Crypto Forecast: Up 23.5% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 11.1% Today

Solana ($SOL) Crypto Forecast: Up 9.0% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 10.2% Today

Sui ($SUI) Crypto Forecast: Up 10.0% Today

Copper ($COPPER) Commodity Forecast: Up 1.3% Today

Regeneron Pharmaceuticals Inc. Price History

06.00.2025 - REGN Stock was up 1.9%

• Despite signs of bearish sentiment from financial giants through unusual options activity, the stock displayed a robust bullish movement, contrary to expectations.
• The divergence between options activity and market performance could be due to favorable developments or news within the company that overshadowed the bearish sentiment.
• Positive clinical trial outcomes, regulatory approvals, or strong financial results may have influenced the upward movement in REGN's stock price.
• Investors potentially responded well to the company's strategic choices or growth outlook, contributing to the surprising bullish movement despite the bearish options activity.

04.01.2025 - REGN Stock was up 5.1%

• Regeneron reported impressive Q4 earnings, with adjusted EPS surpassing estimates and sales exceeding expectations, driven by growth in key products like Eylea and Libtayo.
• The company's decision to introduce a dividend and implement a stock buyback program likely enhanced investor confidence in its future prospects.
• Despite facing legal challenges and lawsuits related to securities law violations, the favorable earnings report and strategic financial moves overshadowed these issues, resulting in a rise in the stock price.
• Anticipation among investors for a strong performance in Dupixent and Eylea HD in the upcoming earnings report led to increased positivity and contributed to the bullish outlook for Regeneron Pharmaceuticals.

04.01.2025 - REGN Stock was up 2.8%

• The bullish movement in REGN's stock could be attributed to investors' anticipation of a positive earnings report for the fourth quarter of 2024.
• Despite facing a class-action lawsuit for securities law violations, investors seem optimistic about REGN's future performance, possibly due to the potential success of its key drugs like Dupixent and Eylea HD.
• The lawsuit may have already been factored into the stock price, leading investors to focus more on the company's operational performance and growth prospects.
• Overall, the market seems to be reacting favorably to REGN's potential earnings beat and the strength of its product portfolio, overshadowing the legal challenges the company is currently facing.

05.01.2025 - REGN Stock was up 7.2%

• REGN experienced a strong bullish movement after reporting better-than-expected Q4 earnings, with adjusted EPS of $12.07 surpassing consensus estimates.
• The initiation of a dividend program and additional stock buyback program by Regeneron further boosted investor confidence in the company's financial stability and growth prospects.
• Despite a slight decline in Eylea sales in the United States due to competition, the overall sales growth of 10% to $3.79B and the surge in sales of other drugs like Libtayo contributed to the positive market response.
• The lawsuit against Regeneron for securities law violations may have initially caused some uncertainty, but the strong earnings report and strategic financial decisions overshadowed these concerns, leading to the bullish market movement.

19.11.2024 - REGN Stock was down 5.2%

• The bearish movement in REGN today could be attributed to Eylea HD showing non-inferiority to Eylea in a phase III study, raising concerns about potential competition within Regeneron's product line.
• The announcement of REGN's presentation at the J.P. Morgan Healthcare Conference might not have met market expectations for clear growth strategies or developments.
• The successful results of Eylea's higher dose formulation in treating another form of retinal disease might have been overshadowed by concerns about declining Eylea sales. This mixed performance of their lead drug could have influenced the bearish sentiment surrounding REGN.
• Overall, the market's reaction to recent events and REGN's performance this year, with a 15.5% decline, suggests investors are adopting a cautious approach, waiting for clearer signals of growth and stability before making significant moves in the stock.

13.00.2025 - REGN Stock was up 5.2%

• Despite facing a 35.6% decline in the past six months due to Eylea's sales drop, REGN saw a surge today, possibly indicating a shift in investor sentiment.
• The class action lawsuits against REGN might have initially impacted the stock negatively, but the market's reaction today suggests investors are optimistic about the company's future prospects.
• The upcoming financial results announcement on February 4, 2025, could be generating positive anticipation among investors, leading to the bullish movement in REGN's stock price.

08.04.2025 - REGN Stock was down 6.5%

• The stock price of Regeneron Pharmaceuticals experienced a significant decline today, despite a slight increase in the current market session.
• The downward trend in the stock price could be attributed to the overall market sentiment affecting biotech and pharmaceutical companies.
• Investors might be reacting to the stock's performance over the past month and year, where it has shown a notable decrease, possibly leading to profit-taking or market corrections.
• While Regeneron Pharmaceuticals has historically outperformed the market over the long term, short-term fluctuations can be influenced by various factors, including industry news and market conditions.

06.04.2025 - REGN Stock was down 5.1%

• REGN stock's decline could be linked to profit-taking following a period of market outperformance.
• Investor sentiment may be influenced by negative developments or uncertainties related to Regeneron Pharmaceuticals.
• Overall market trends or sector-specific factors might have contributed to REGN stock's downward trajectory.
• The decrease in Regeneron Pharmaceuticals' stock value could be a result of investors reallocating their investments to alternative opportunities.

12.02.2025 - REGN Stock was down 5.5%

• The bearish movement in REGN today could be attributed to profit-taking by investors after the stock's significant outperformance over the past 20 years.
• Positive discussions about the impressive historical returns of REGN might have influenced investors to sell their positions today, resulting in downward pressure on the stock.
• Market participants could be reevaluating their positions in REGN due to its high market capitalization, leading to a temporary decline in the stock price.

07.02.2025 - REGN Stock was up 5.1%

• REGN stock showed a strong bullish movement today.
• The positive recommendation for conditional marketing authorization for REGN's linvoseltamab to treat multiple myeloma is likely responsible for boosting investor confidence in the company's drug pipeline.
• This development hints at a possible new revenue source for Regeneron, leading to increased optimism among investors and influencing the bullish market movement.
• Investors may interpret this event as a significant milestone for Regeneron's expansion into the oncology market, contributing to the positive sentiment surrounding the stock.

29.03.2025 - REGN Stock was down 10.1%

• The bearish movement in REGN today could be attributed to investor concerns about the upcoming Q1 earnings.
• The focus on the performance of key drugs like Dupixent and Eylea HD may have led to uncertainty and profit-taking among investors.
• The market might be reacting to any potential signs of underperformance or lower-than-expected sales figures for these key products.
• Investors may be adjusting their positions in anticipation of the earnings, leading to the bearish movement in REGN today.

30.03.2025 - REGN Stock was up 5.5%

• Regeneron Pharmaceuticals Inc. (REGN) experienced a strong bullish movement today.
• The positive market sentiment could be attributed to potential breakthroughs in the company's research and development pipeline, driving investor confidence in its future prospects.
• Investors may also be reacting to favorable regulatory developments or promising clinical trial results, further boosting REGN's stock price.
• Overall, the bullish movement in REGN reflects growing optimism in the biotechnology sector and the company's ability to deliver innovative solutions to pressing healthcare challenges.